Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
55%
Abiraterone
22%
Ablative Therapy
100%
Androgen Receptor
100%
Androgen Signaling
11%
Androgens
11%
Bipolar Androgen Therapy
100%
Castration-resistant Prostate Cancer
100%
Clinical Response
11%
Co-agonist
11%
Cohort Trial
11%
Disease Stabilization
11%
Enzalutamide
22%
Favorable Outcome
11%
High-dose Testosterone
11%
Hormonal Therapy
33%
Intramuscularly
11%
Luteinizing Hormone
11%
Metastatic Cancer
22%
Multi-cohort
11%
Overcoming Resistance
11%
Patients with Cancer
22%
Previously Treated
11%
Radiographic Progression-free Survival
11%
Resistance Studies
11%
Response Rate
11%
Signal Inhibition
11%
Single Center
11%
Supraphysiological
11%
Testosterone
11%
Testosterone Administration
11%
Testosterone Cypionate
11%
Therapy Treatment
11%
Trial Registration
11%
Well Tolerated
11%
Medicine and Dentistry
Abiraterone
22%
Ablation Therapy
100%
Agonist-Antagonist
11%
Androgen
22%
Androgen Receptor
100%
Androgen Therapy
100%
Castration Resistant Prostate Cancer
100%
Diseases
11%
Drug Megadose
11%
Enzalutamide
22%
Gonadorelin Agonist
11%
Hormone Therapy
22%
Malignant Neoplasm
11%
Metastatic Carcinoma
22%
Progression Free Survival
11%
Testosterone
22%
Testosterone Cipionate
11%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone
18%
Agonist-Antagonist
9%
Androgen
100%
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Diseases
9%
Enzalutamide
18%
Gonadorelin Agonist
9%
Hormone Cancer Therapy
18%
Malignant Neoplasm
27%
Progression Free Survival
9%
Testosterone
18%
Testosterone Cipionate
9%